RxDoctor Payments Data

Scott Hall, MD

Internal Medicine · Fort Lauderdale, FLNPI 1972578219

Payments from drug & device makers

$3,067in general payments, 2019–2025

Across 152 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$1K
  • Johnson & Johnson$269
  • Theratechnologies Inc.$134
  • Novo Nordisk$75
  • Merck$28
  • plus $102 from 6 others

What the payments were for

  • Food & beverage$3,067100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,067 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$42,029
Medicare patients
111
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala313$1,361,686
JulucaDolutegravir/Rilpivirine100$400,842
TriumeqAbacavir/Dolutegravir/Lamivudi89$326,672
DescovyEmtricitabine/Tenofov Alafenam120$289,455
TivicayDolutegravir Sodium112$267,112
PrezcobixDarunavir/Cobicistat68$184,133
RukobiaFostemsavir Tromethamine18$165,423
IsentressRaltegravir Potassium39$92,208
GenvoyaElviteg/Cob/Emtri/Tenof Alafen22$89,214
DovatoDolutegravir Sodium/Lamivudine21$74,108
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$70,086
PifeltroDoravirine33$59,585
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$54,608
Darunavir50$40,600
EliquisApixaban43$29,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$1,388$1,740,355455 claims
Viiv Healthcare CompanyJuluca, Triumeq, Tivicay, Rukobia, Dovato$1,072$1,234,157340 claims
Johnson & JohnsonPrezcobix$269$184,13368 claims
MerckIsentress, Pifeltro$28$151,79372 claims
PfizerEliquis$19$29,55343 claims
Novo NordiskOzempic$75$22,13420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →